Related Experiment Video
Updated: Apr 1, 2026

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation
Published on: March 15, 2020
Pradaxa-induced esophageal ulcer.
1Kaiser Permanente Colorado, Aurora, Colorado, USA.
Pradaxa (dabigatran) may cause esophageal ulcers due to its tartaric acid formulation. Proper administration is crucial to prevent this rare adverse event in patients with atrial fibrillation.
Area of Science:
- Gastroenterology
- Pharmacology
- Cardiology
Background:
- Pradaxa (dabigatran) is a direct thrombin inhibitor used for stroke prevention in non-valvular atrial fibrillation.
- Esophageal adverse events are a potential concern with oral medications.
Related Concept Videos
Esophageal Varices-I: Introduction
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Venous Thrombosis III: Interprofessional Care
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

